DDInter1398 DDInter1676
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Pasireotide {u} (Compound) resembles {v} (Compound) Terlipressin
Pasireotide {u} (Compound) binds {v} (Gene) SSTR5
Pasireotide {u} (Compound) is included by {v} (Pharmacologic Class) Somatostatin Receptor Agonists
Pasireotide {u} (Compound) causes {v} (Side Effect) Abdominal pain
Pasireotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pasireotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoprolol
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Protriptyline
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Pasireotide (Compound) resembles Terlipressin (Compound)
Pasireotide (Compound) binds SSTR5 (Gene)
Pasireotide (Compound) is included by Somatostatin Receptor Agonists (Pharmacologic Class)
Pasireotide (Compound) causes Abdominal pain (Side Effect)
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Doravirine
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol
Pasireotide may lead to a major life threatening interaction when taken with Protriptyline
Pasireotide may lead to a major life threatening interaction when taken with Fingolimod